Stephens announced Matt Dormer and Chris Cooley will join the firm’s Investment Banking division as Managing Directors to focus on Health and Life Sciences. Mr. Dormer is joining Stephens from another firm while Mr. Cooley is transferring from Stephens’ equity research team.

“Stephens continues to strengthen our offering within Health and Life Sciences, and the addition of Matt and Chris represents a substantial expansion of the group’s coverage and capabilities. We are very excited to have them as part of the team,” said Brad Eichler, Executive Vice President and Head of Investment Banking.

Mr. Dormer has more than 20 years of experience in the biotechnology industry. Prior to joining Stephens, he was an Investment Banker at Oppenheimer & Co., Laidlaw & Co, and Summer Street Research Partners. Mr. Dormer started his financial career in Equity Research at Fulcrum Global Partners covering the Biotech sector before transitioning to Investment Banking. Mr. Dormer earned a Bachelor of Science in Biology from Davidson College and his Masters in Business Administration from Northeastern University. He will be based in Stephens’ Boston office.

Mr. Cooley has more than 28 years of experience and joined Stephens in 2010 to lead coverage of the Medical Device and Hospital Supply sector. Mr. Cooley began his professional career with Dean Witter and worked for Cargill, Morgan Keegan, SunTrust Equitable Securities and FTN Equity Capital Markets. He has been recognized by The Wall Street Journal and Financial Times for the accuracy of his financial insights and has presented at multiple corporate events. Mr. Cooley earned a Bachelor of Science in Economics from the University of Arkansas and a Masters in Business Administration from the University of Tennessee. He will be based in Stephens’ Little Rock office.

Stephens’ Health and Life Sciences team creates innovative solutions for firms that produce equipment and therapeutics, deliver care and support medical facilities.